Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.
Also called NCT03217825
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Windtree Therapeutics
- Registry
-
NCT03217825
-
- Other papers using this trial's data
- Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT03217825. Randomized; triple masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2018-02-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan
- Condition
- Hypertension
- Intervention (Drug)
- Rostafuroxin
- Intervention (Drug)
- Losartan
- Lead sponsor
- Windtree Therapeutics
Record details
- Record id
cardio:ct-nct03217825- Content hash
48fa2797242536220b5cf88f43c9b780b29c715979e5b1fd18c79f7fc7e50552